Stoke Therapeutics names Thomas McCauley chief scientific officer

Stoke Therapeutics

Stoke Therapeutics

STOK

0.00
  • Stoke Therapeutics appointed Thomas McCauley as chief scientific officer to lead scientific strategy, pipeline expansion, and execution across its RNA medicines platform.
  • McCauley most recently served as president and CEO of Neptune Bio.
  • He previously held chief scientific officer roles at Omega Therapeutics, Macrolide Pharmaceuticals, and Translate Bio.
  • Stoke’s lead investigational medicine, zorevunersen, remains in development as a potential disease-modifying treatment for Dravet syndrome.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607130730BIZWIRE_USPR_____20260713_BW413645) on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.